Haiou Yang

Dr. Haiou Yang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HYHaiou Yang
Haiou Yang
QMQianqian Ma
Qianqian Ma
YWYu Wang
Yu Wang
ZTZhenhua Tang
Zhenhua Tang
During pregnancy in humans, the physiology of the mother and foetus are finely regulated by many factors. Inappropriate regulation can result in pregnancy disorders, such as complications and foetal abnormalities. The early prediction or accurate diagnosis of related diseases is a concern of researchers. Liquid biopsy can be analysed for circulating cells, cell-free nucleic acids, and exosomes. Because exosomes can be detected in the peripheral blood of women in early pregnancy, these vesicles and their contents have become the focus of early prediction or diagnostic biomarker research on pregnancy complications and foetal developmental disorders. In this review, we focus on recent studies addressing the roles of peripheral blood exosomes and circulating miRNAs in pregnancy complications and in pregnancies with abnormal foetal developmental disorders, with particular attention paid to the potential application value of exosomes and circulating miRNAs as disease-specific biomarkers.

16 October 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
YYYa‐Nan Yin
Ya‐Nan Yin
LCLi Cao
Li Cao
JWJie Wang
Jie Wang
YCYu‐Ling Chen
Yu‐Ling Chen
HYHaiou Yang
Haiou Yang
JZJian-Yuan Zhao
Jian-Yuan Zhao
Prenatal diagnosis of congenital heart disease (CHD) relies primarily on fetal echocardiography conducted at mid‐gestational age—the sensitivity of which varies among centers and practitioners. An objective method for early diagnosis is needed. Here, we conducted a case–control study recruiting 103 pregnant women with healthy offspring and 104 cases with CHD offspring, including VSD (42/104), ASD (20/104), and other CHD phenotypes. Plasma was collected during the first trimester and proteomic analysis was performed. Principal component analysis revealed considerable differences between the controls and the CHDs. Among the significantly altered proteins, 25 upregulated proteins in CHDs were enriched in amino acid metabolism, extracellular matrix receptor, and actin skeleton regulation, whereas 49 downregulated proteins were enriched in carbohydrate metabolism, cardiac muscle contraction, and cardiomyopathy. The machine learning model reached an area under the curve of 0.964 and was highly accurate in recognizing CHDs. This study provides a highly valuable proteomics resource to better recognize the cause of CHD and has developed a reliable objective method for the early recognition of CHD, facilitating early intervention and better prognosis.

18 February 2025 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
DYDongting Yao
Dongting Yao
XTXinyu Tang
Xinyu Tang
MXMinghui Xue
Minghui Xue
KZKeyu Zhu
Keyu Zhu
WLWei Li
Wei Li
ZLZhiwei Liu
Zhiwei Liu
This retrospective cohort study aimed to investigate the correlation between vaginal infections and adverse pregnancy outcomes in a Chinese obstetric population. This study was conducted at the International Peace Maternity and Child Health Hospital in Shanghai from 2021 to 2023. The primary objective was to assess the incidence of various vaginal infections and their associations with preterm birth (PTB), low birth weight (LBW), and preterm premature rupture of membranes (PPROM). Data were collected from medical records, with vaginal infection diagnoses confirmed through standard laboratory procedures. This study included women who registered and delivered at our hospital between 2021 and 2023. Strict exclusion criteria were applied to control confounding factors, excluding women with a history of syphilis, human immunodeficiency virus infection, hepatitis virus infection, or non-live birth outcomes. Continuous variables were analyzed using the Mann–Whitney U test, whereas categorical variables were assessed using the Pearson chi-square test or Fisher exact test. Logistic regression analysis was employed for multivariate assessments to determine whether vaginal infections were independent risk factors for adverse pregnancy outcomes. Vaginal infections were significantly associated with adverse pregnancy outcomes. Women with vaginal infections had higher rates of PTB (15.65% vs. 9.16%, P < 0.001), LBW (10.82% vs. 5.93%, P < 0.001), and PPROM (7.41% vs. 5.31%, P < 0.001) compared with their uninfected counterparts. Mixed vaginitis demonstrated a stronger association with these adverse outcomes compared with single infections. The timing of infection during pregnancy emerged as a critical determinant of the risk of adverse outcomes. The study underscores the critical need for comprehensive screening and management of vaginal infections during pregnancy to improve maternal and neonatal health. Targeted interventions, particularly in the later stages of pregnancy, are essential to mitigate the risks associated with vaginal infections. Future research should focus on developing more effective screening methods and therapeutic strategies to address the specific types of vaginal infections and their effects on pregnancy outcomes.

18 April 2024 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
DHDeyu Hu
Deyu Hu
JQJun Qian
Jun Qian
FYFenghua Yin
Fenghua Yin
BWBing Wei
Bing Wei
JWJiayu Wang
Jiayu Wang
HYHaiou Yang
Haiou Yang

6 April 2022 in Research Square
Verified
Preprint
Open access
PDF file
DHDeyu Hu
Deyu Hu
JQJun Qian
Jun Qian
FYFenghua Yin
Fenghua Yin
BWBing Wei
Bing Wei
WHWeiping Hu
Weiping Hu
HYHaiou Yang
Haiou Yang
Background: This study aimed at exploring a panel of novel biomarker for early detection of high-grade serous ovarian cancer (HGSOC). Methods: The serum levels of CA125, CA724 and HE4 were compared among serum samples collected from patients with HGSOC, borderline malignancy or benign gynecologic pathologies. Univariable and multivariable logistic regression analyses were performed to identify the risk factors of HGSOC. Nomogram was established for predicting HGSOC using the risk factors. Receiver operating characteristic (ROC) curves was plotted and the area under the curve (AUC), sensitivity and specificity of the CA125, CA724, HE4, ROMA and new panel were calculated.Results: The serum concentration of CA125, CA724 and HE4 were increased among patients with HGSOC. The AUC of CA125, CA724, HE4, ROMA2 and the new panel based on age, CA125 and ROMA2 were 0.732 (0.646-0.818), 0.773 (0.699-0.847), 0.886 (0.831-0.941), 0.835 (0.763-0.907), and 0.933 (0.896-0.969), respectively. Nomogram was constructed to diagnose HGSOC based on CA125, age and ROMA2. The C-indices of this nomogram was 0.88 (95% CI= 0.81-0.95) in training cohort and 0.91 (95% CI= 0.86-0.96) in the validation cohort. The sensitivity and specificity were 89.66% and 82.44% in diagnosing HGSOC, and the positive predictive value and negative predictive value of new algorithm were 69.33% and 94.74%, respectively.Conclusion: The new index based on age, CA125 and ROMA2 could be a new auxiliary diagnostic indicator in distinguishing HGSOC from borderline malignancy.

10 December 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
YLYa-Min Liu
Ya-Min Liu
WHWei Huang
Wei Huang
YTYong-Zhe Tang
Yong-Zhe Tang
HZHai Zhang
Hai Zhang
SQSheng-Ying Qin
Sheng-Ying Qin
XZXiaoqing Zhang
Xiaoqing Zhang
Docetaxel is a first-line chemotherapy drug for breast cancer and is traditionally dosed based on body surface area (BSA). However, this method often leads to significant inter-patient variability and a high incidence of adverse drug reactions (ADRs). Therapeutic drug monitoring (TDM) offers a personalized dosing approach that may improve drug safety and efficacy. This study aimed to evaluate the clinical and pharmacoeconomic benefits of TDM-guided dosing compared to traditional BSA-based dosing in breast cancer patients receiving docetaxel-based chemotherapy. A randomized controlled study was conducted at the Department of Breast Surgery, IPMCH, from October 2022 to July 2024. A total of 208 breast cancer patients were enrolled and randomly assigned to two groups: the BSA group (n = 104) and the TDM-guided pharmacokinetics (PK) group (n = 104). Adverse drug reactions-including hematological, gastrointestinal, skin, neurotoxic, and cardiotoxic events-were monitored and compared between groups. Liver function markers (ALT, AST, ALP) and pharmacoeconomic data (treatment-related costs) were also assessed. Statistical analyses included univariate and interaction models to evaluate the impact of dosing strategy on ADRs and costs. Patients in the TDM-guided PK group exhibited significantly lower levels of ALT, AST, and ALP, indicating reduced hepatic toxicity. Gastrointestinal ADRs-including nausea, diarrhea, and constipation-were less frequent and less severe in the PK group compared to the BSA group. Overall, the incidence and severity of ADRs were markedly reduced in the PK group. Pharmacoeconomic analysis demonstrated consistently lower treatment-related costs in the PK group. Both univariate and interaction analyses confirmed the clinical and economic benefits of TDM-guided dosing. TDM-guided docetaxel dosing significantly reduced ADRs and improved cost efficiency in breast cancer chemotherapy. These findings support the implementation of TDM as a superior strategy to traditional BSA-based dosing, with potential to enhance both patient safety and healthcare resource utilization.